Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Anti-IL-6

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    26 result(s) found for: Anti-IL-6. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2006-001671-38 Sponsor Protocol Number: C0328T07 Start Date*: 2007-05-23
    Sponsor Name:Centocor B.V.
    Full Title: A Phase 2 Multicenter, Open-label Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) in Combination with Mitoxantrone versus Mitoxantrone in Subjects with Metastatic Hormone-Refractory Prostate Canc...
    Medical condition: Metastatic Hormone-Refractory Prostate Cancer (HRPC)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) BE (Completed) AT (Completed) FR (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-012380-34 Sponsor Protocol Number: CNTO328MCD2001 Start Date*: 2010-05-18
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Su...
    Medical condition: Multicentric Castleman's disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050251 Castleman's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed) DE (Completed) FR (Completed) NL (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2020-001616-18 Sponsor Protocol Number: TACTIC-COVID Start Date*: 2020-04-18
    Sponsor Name:Fundació Clinic per a la Recerca Biomèdica
    Full Title: Treatment with inhaled corticoids in patients with COVID-19 admitted to hospital with pneumonia
    Medical condition: COVID19
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10051905 Coronavirus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001904-36 Sponsor Protocol Number: C0328T06 Start Date*: 2006-09-07
    Sponsor Name:Centocor B.V.
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study Comparing the Combination of CNTO 328 (Anti-IL-6 Monoclonal Antibody) and Velcade® versus Velcade alone in Subjects with Relapsed or Re...
    Medical condition: relapsed or refractory multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) FR (Completed) GB (Completed) CZ (Completed) PT (Completed) DE (Completed) GR (Completed) BG (Completed) SK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-017237-22 Sponsor Protocol Number: CNTO328MMY3001 Start Date*: 2011-01-31
    Sponsor Name:Janssen Biologics B.V.
    Full Title: A Phase 3, Randomized, Double-blind Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) or Placebo in Combination With VELCADE and Dexamethasone for the Treatment of Subjects With Relapsed or Refra...
    Medical condition: Subjects With Relapsed or Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) ES (Completed) CZ (Prematurely Ended) PT (Completed) NL (Prematurely Ended) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022243-38 Sponsor Protocol Number: CNTO136ARA3003 Start Date*: 2012-07-11
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Activ...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) DE (Completed) GB (Completed) AT (Completed) ES (Completed) PT (Completed) BE (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-002476-13 Sponsor Protocol Number: 20HH5958 Start Date*: 2020-07-24
    Sponsor Name:Imperial College London
    Full Title: A study to assess the safety and efficacy of Clazakizumab in patients with COVID-19 and kidney disease.
    Medical condition: Patients with kidney disease who are hospitalised with COVID-19 infection with pulmonary involvement (i.e. consistent chest imaging abnormalities) and clinical deterioration (i.e increasing oxygen ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10023417 Kidney dysfunction LLT
    20.0 100000004862 10047463 Viral infection NOS LLT
    20.0 10022891 - Investigations 10063321 Interleukin level PT
    20.1 10041244 - Social circumstances 10079637 Dependence on oxygen therapy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-004078-24 Sponsor Protocol Number: SARIPET_2019.099_version_1.1 Start Date*: 2020-05-07
    Sponsor Name:IDIVAL
    Full Title: Effect of Sarilumab on atherosclerotic disease measured by PET/CT (Positron Emission Tomography/Computed Tomography) in Rheumatoid Arthritis
    Medical condition: RHEUMATOID ARTHRITIS
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022242-24 Sponsor Protocol Number: CNTO136ARA3002 Start Date*: 2012-07-11
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Activ...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2020-001618-39 Sponsor Protocol Number: CL08-ORY-2001_COVID-19 Start Date*: 2020-04-24
    Sponsor Name:Oryzon Genomics S. A.
    Full Title: A Phase II, randomized, open–label study to evaluate the efficacy and tolerability of treatment with vafidemstat in combination with standard of care treatment to prevent Acute Respiratory Distress...
    Medical condition: Acute Respiratory Distress Syndrome (ARDS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10003083 ARDS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-002790-22 Sponsor Protocol Number: ML39921 Start Date*: 2019-04-11
    Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
    Full Title: Tocilizumab in Graves’ Orbitopathy (TOGO). Multicenter, randomized, observer-blind, controlled study of the anti-IL-6 receptor antibody tocilizumab (TCZ) or methylprednisolone (MP) treatment in pat...
    Medical condition: Active moderate-severe Graves' Orbitopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10015684 Exophthalmos endocrine LLT
    20.1 100000004853 10014702 Endocrine exophthalmos LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001604-30 Sponsor Protocol Number: 1001 Start Date*: 2017-12-11
    Sponsor Name:Medical University of Vienna
    Full Title: Safety, Tolerability and Efficacy of anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Rejection after Kidney Transplantation - A Pilot Trial
    Medical condition: Antibody-mediated rejection of a kidney transplant
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001735-22 Sponsor Protocol Number: CNTO328SMM2001 Start Date*: 2011-09-28
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Siltuximab (Anti IL 6 Monoclonal Antibody) in Subjects with High-risk Smoldering Multiple Myeloma
    Medical condition: High-risk Smoldering Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10028233 Multiple myeloma without mention of remission LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) SE (Completed) FR (Completed) GR (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004763-72 Sponsor Protocol Number: IM133-005 Start Date*: 2012-06-26
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase IIb, Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Dose-Ranging Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with BMS-945429 in Subj...
    Medical condition: Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) DE (Completed) CZ (Prematurely Ended) NL (Prematurely Ended) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003756-16 Sponsor Protocol Number: BP43445 Start Date*: 2022-03-18
    Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
    Full Title: A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE MASKED, ACTIVE COMPARATORCONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7200220 ADMINIST...
    Medical condition: Diabetic Macular Edema (DME)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) CZ (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023956-99 Sponsor Protocol Number: IM133-001 Start Date*: 2011-08-17
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotre...
    Medical condition: RHEUMATOID ARTHRITIS,NOS
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004859 10039076 Rheumatoid arthritis and other inflammatory polyarthropathies LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) NL (Completed) DE (Prematurely Ended) CZ (Prematurely Ended) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020968-38 Sponsor Protocol Number: CNTO136LUN2001 Start Date*: 2011-03-17
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate Efficacy and Safety of Treatment with CNTO 136 Administered Intravenously in Subjects with Active Lup...
    Medical condition: Active Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-005704-13 Sponsor Protocol Number: CO328X05 Start Date*: 2007-05-25
    Sponsor Name:Queen Mary, University of London
    Full Title: A Phase II Study of Intravenous CNTO328 in Patients with Recurrent Epithelial Ovarian Cancer
    Medical condition: This is a Phase II trial to determine the efficacy of intravenous CNTO 328 in women with the following diseases: recurrent epithelial ovarian cancer, Fallopian tube carcinoma, primary peritoneal ca...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066697 Ovarian cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004931-39 Sponsor Protocol Number: ALD518-CLIN-003 Start Date*: 2008-12-08
    Sponsor Name:Alder Biopharmaceuticals, Inc
    Full Title: A Study to Determine the Safety, Efficacy, and Pharmacokinetics of 80 mg, 160 mg, and 320 mg ALD518 versus Placebo Administered as Multiple Intravenous Infusions to Patients with Active Rheumatoid ...
    Medical condition: Active Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-004390-31 Sponsor Protocol Number: BP43464 Start Date*: 2022-06-06
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE MASKED, ACTIVE COMPARATORCONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7200220 IN COMBI...
    Medical condition: Diabetic Macular Edema (DME)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 22:51:19 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA